To be eligible for treatment in the program, patients must be referred by a physician, have had a confirmed COVID-19 infection and be experiencing persistent symptoms.
As part of the program, patients receive an in-person evaluation from an infectious diseases or pulmonary medicine expert who can refer them to a network of specialists including cardiologists, pulmonologists, neurologists and psychiatrists. The program also provides patients with access to clinical trials being conducted by Cedars-Sinai investigators.
“Given the sheer number of people worldwide who have had COVID-19 — more than 90 million — if even 1 percent experience symptoms beyond three months, that is a huge number of patients who need help,” said Catherine Lee, MD, the program’s co-director an an infectious disease specialist at the health system.
The program works alongside the Smidt Heart Institute’s Post-COVID-19 Cardiology Program, which enrolls patients diagnosed with a heart issue associated with post-COVID-19 recovery, and the Cedars Sinai Department of Medicine’s Post-ICU Clinic, which treats intensive care unit patients who developed respiratory and neurological problems after discharge.
More articles on patient safety and outcomes:
Busy ICU linked to increase in COVID-19 deaths, study finds
Schizophrenia 2nd greatest risk factor for COVID-19 death, study finds
CMS limits on-site complaint, recertification surveys
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
